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Abstract. Radiation‑induced fibrosis is one of the late compli-
cations of radiotherapy (RT) for nasopharyngeal carcinoma 
(NPC). The aim of this study was to investigate the association 
between X‑ray repair cross‑complementing protein 1 and 3 
(XRCC1 and XRCC3, respectively) gene haplotypes and radi-
ation‑induced fibrosis in NPC patients. Genomic DNA was 
extracted from blood samples of 120 NPC patients previously 
treated with RT. In total, 12 tag single‑nucleotide polymor-
phisms (SNPs) were selected from the XRCC1 and XRCC3 
genes and were genotyped using restriction fragment length 
polymorphism analysis or unlabeled probe melting analysis. 
Single‑marker and haplotype analyses were performed using 
multivariate logistic regression analysis. The functional variant 
rs861539 of XRCC3 may be associated with radiation‑induced 
fibrosis [asymptotic P‑value (Pasym)<0.05]. No significant 
association was observed between radiation‑induced fibrosis 
and any of the tag SNPs of XRCC1 and XRCC3 in either 
single‑marker or haplotype analysis after 10,000 permutations 
[empirical P‑value (Pemp)>0.05]. Our preliminary results indi-
cated that the rs861539 variant of XRCC3 may be associated 
with an increased risk of radiation‑induced fibrosis; however, a 
large‑scale study is required to confirm this result.
Introduction
Nasopharyngeal carcinoma (NPC) is a common type of cancer 
in Southern China, whereas its incidence in Western countries 
is relatively low (1). Due to its deep‑seated anatomic location 
and relative radiosensitivity, radiotherapy (RT) is the treatment 
of choice for primary NPC. Advanced RT techniques, such 
as intensity‑modulated RT (IMRT) have achieved improve-
ments the locoregional control of the tumour and reduced the 
incidence of complications (2). However, radiation‑induced 
fibrosis remains one of the major late complications, regard-
less of the treatment method (2,3). Since different patients may 
present with different degrees of skin fibrosis despite receiving 
identical treatment, it was hypothesized that the severity of 
such complications may be genetically determined. Previous 
studies investigated the association of single‑nucleotide poly-
morphisms (SNPs) in genes involved in DNA repair, such as 
X‑ray repair cross‑complementing protein 1 (XRCC1) rs25487 
(c.1196A>G, p.Gln399Arg) and X‑ray repair cross‑comple-
menting protein 3 (XRCC3) rs861539 (c.722C>T, p.Thr241Met) 
with late complications in various types of cancer (4‑18).
The identification of particular functional variants in 
cancer patients prior to the initiation of any treatment is likely 
to improve the prediction of the severity of radiation‑induced 
complications in individual patients, leading to improved 
patient care and customization of treatment protocols. Since 
the majority of studies were conducted in Caucasian popula-
tions and allelic frequencies vary between ethnic groups, little 
is known regarding the association between genetic variants 
and post‑RT complications in Chinese patients. The previously 
published studies mainly focused on particular functional 
variants of candidate genes; however, common genetic vari-
ants were overlooked. Therefore, this preliminary study aimed 
to evaluate the association of radiation‑induced fibrosis with 
XRCC1 and XRCC3 functional variants and possible haplo-
types in Chinese NPC patients.
Materials and methods
Subject recruitment. A total of 120 Chinese NPC patients, 
including 70.8% men and 29.2% women, aged ≥18 years, 
without distant metastasis, who were treated with conven-
tional RT (CRT) or IMRT, were recruited during their 
follow‑up between 2010 and 2011 at the Department of 
Clinical Oncology, Queen Mary Hospital, Hong Kong 
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(Table I). RT was administered at 2 Gy per fraction, 5 frac-
tions per week for 6‑7 weeks. The patients who received CRT 
and IMRT generally received a total dose of 66‑68 Gy and 
70‑76 Gy to the tumour, respectively. The patients were clas-
sified as ‘cases’ if they presented with persistent ≥grade 1 
fibrosis at the time of the follow‑up, according to the radia-
tion morbidity scoring criteria published by the Radiation 
Therapy Oncology Group. Patients without significant 
fibrotic changes (grade 0) for ≥2‑years post‑RT were classi-
fied as ‘controls’. All the patients signed a written informed 
consent form prior to enrolment.
Tag SNP selection and genotyping. The selection of the tag 
SNPs of XRCC1 and XRCC3 was performed with Tagger soft-
ware (Cambridge, MA, USA) using the International HapMap 
Project data for Han Chinese subjects (release 27, phase II+III, 
Feb 9) (19,20). Tag SNPs were selected using a pairwise tagging 
algorithm, r2=0.8 and a minor allele frequency (MAF) of ≥0.2. 
Previously reported SNPs were also included in the analysis. 
In order to capture any upstream and downstream regula-
tory elements of the candidate gene, tag SNPs were selected 
from 3 kb at the start and the end of the candidate region. A 
total of 12 tag SNPs were selected and were genotyped using 
restriction fragment length polymorphism analysis (RFLP) or 
unlabeled probe melting analysis.
Genotyping method. For the DNA analysis of each patient, 
6 ml venous blood was collected in ethylenediaminetetraacetic 
acid (EDTA) tubes. DNA was extracted using a FlexiGene 
DNA kit (Qiagen, Hilden, Germany). The concentration of 
DNA was measured using NanoDrop™ 1000 Spectropho-
tometer (Thermo Fisher Scientific, Wilmington, MA, USA). 
The DNA concentration was adjusted to 10 ng/µl using Tris‑
EDTA buffer for polymerase chain reaction (PCR). A total of 
10 µl reaction mixture was used for both RFLP and unlabeled 
probe melting analysis. Each reaction mixture contained 10 ng 
of genomic DNA, 0.2 mM of each deoxynucleotide triphos-
phate, 0.3 U of HotStarTaq Plus DNA polymerase with 1X 
PCR buffer [containing Tris‑Cl, KCl, (NH4)2SO4 and 15 mM 
MgCl2, pH 8.7] (Qiagen) and specific optimized primers and 
MgCl2 concentrations.
Statistical analysis. Genotyped data were analyzed using 
the PLINK statistical package (http://pngu.mgh.harvard.
edu/~purcell/plink), version 1.07 (21). The genotypes in the 
control and case groups were tested for deviation from the 
Hardy‑Weinberg equilibrium (HWE) using the Fisher's exact 
test and the odds ratio (OR) for each genotype was calculated. 
Analysis of single markers was performed using the PLINK 
toolset. Gender, age, treatment regimen and other clinical 
factors were assessed by multivariate logistic regression 
analysis. Analyses of all the possible haplotypes using the 
sliding window approach were also performed using PLINK. 
Empirical P‑values (Pemp) for single markers, as well as 
haplotype analysis, were generated by multiple comparisons 
based on 10,000 permutations. Genotype data from published 
studies were extracted to perform combined genotype analysis. 
Combined genotype analysis was performed with the Meta 
package, version 2.5.1 in R version 2.15.1 for Windows (http://
cran.r‑project.org/web/packages/meta/index.html) (22).
Results
Group comparison. Of the 120 patients, 45 received CRT 
and 75 received IMRT, whereas 61 patients were treated with 
chemotherapy. A total of 29 patients suffered from ≥grade 1 
neck fibrosis that persisted for ≥2 years. There were signifi-
cantly more patients who received CRT rather than IMRT 
in the case group compared to those in the control group 
(P<0.01). There were also significant differences in the mean 
follow‑up duration (P<0.01) and in the number of men and 
women (P<0.05) between the control and case groups. There 
were no significant differences in the number of patients who 
received chemotherapy, tumor stage and mean age between 
the two groups (P>0.05). All the abovementioned clinical 
factors that may affect the severity of radiation‑induced 
fibrosis were used as covariates in the logistic regression 
analysis.
Statistical analysis. All the tag SNPs were successfully geno-
typed and were in HWE (P>0.05), except the control group of 
tag SNPs rs861544 (P=0.003). This tag SNP was included in 
the analysis, since ~1 significant result could be obtained due 
to random chance with 12 comparisons when α=0.05.
Single‑marker multivariate logistic regression analysis 
revealed that only the T allele of rs861539 was associated with 
increased risk of fibrosis [asymptotic P‑value (Pasym)=0.0116; 
OR=3.88]. However, a significance level was lost after 
multiple comparisons (Pemp=0.0632). There was no significant 
association between fibrosis and the remaining tag SNPs in 
the single‑marker multivariate logistic regression analysis 
(Table II).
Table I. Summary clinical characteristics of recruited patients.
 Controls Cases
Clinical variables (n=91) (n=29) P‑value
Age, years 52.60 (10.46) 55.10 (9.05) NS
[mean (SD)]
Follow‑up, years 8.13 (5.57) 12.38 (5.15) <0.01
[mean (SD)]
Gender, n   <0.05
  Male 69 16
  Female 22 13
TNM stage, n   NS
  I 16 0
  II 26 6
  III 29 15
  IV 16 4
  Unavailable 4 4
Radiotherapy, n   <0.01
  CRT 26 19
  IMRT 65 10
Chemotherapy, n 46 15  NS
NS, not significant; CRT, conventional radiotherapy; IMRT, inten-
sity‑modulated radiotherapy; TNM, tumor node metastasis.
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A total of 42 sliding windows were generated for XRCC1 
and XRCC3, with 21 sliding windows created for each gene. 
No association was found in any of the sliding windows 
following multiple comparisons (omnibus test Pemp>0.05) 
(Table III).
The forest plots of rs25487 from XRCC1 and rs861539 
from XRCC3 in NPC patients are shown in Figs. 1 and 2. The 
percentage of between‑study variation due to heterogeneity is 
presented as I2 (23). There was no significant difference for 
the two SNPs analyzed by the random effects model (P>0.05). 
However, a significant difference was observed when the fixed 
effects model was used for rs25487 (P=0.0415).
Discussion
In this retrospective study, the association of DNA repair 
genes with the development of post‑RT fibrosis in Chinese 
NPC patients was investigated. Selected tag SNPs, as well as 
previously reported functional SNPs that were associated with 
late complications, were determined to obtain comprehensive 
Table II. Summary statistics of selected tag SNPs in the XRCC1 and XRCC3 genes and results of single-marker analysis.
    Genotype counts
    11/12/22  MAF
    ------------------------------------ ---------------------------------
Gene SNPa A1 A2 Control Case Control Case ORb L95 U95 Pasym Pemp
XRCC1 rs3213282 (XRCC1.S1) C G 4/35/52 2/11/16 0.2363 0.2586 1.19 0.53 2.65 0.6975 0.9899
 rs12611088 (XRCC1.S2) T C 7/33/51 1/11/17 0.2582 0.2241 0.59 0.25 1.36 0.2345 0.6137
 rs1001581 (XRCC1.S3) A G 11/46/34 4/13/12 0.3736 0.3621 0.67 0.32 1.39 0.2900 0.7165
 rs3213344 (XRCC1.S4) G C 8/32/51 2/11/16 0.2637 0.2586 1.34 0.64 2.82 0.4430 0.8889
 rs1799782 (XRCC1.S5) T C 8/31/52 2/11/16 0.2582 0.2586 1.40 0.67 2.94 0.3833 0.8289
 rs25487 (XRCC1.S6) A G 6/35/50 1/13/15 0.2582 0.2586 0.80 0.36 1.79 0.6099 0.9705
XRCC3 rs1799794 (XRCC3.S1) G A 17/50/24 6/10/13 0.4615 0.3793 0.65 0.32 1.31 0.2408 0.5839
 rs861530 (XRCC3.S2) G A 19/52/20 8/13/8 0.4945 0.5000 1.08 0.55 2.13 0.8371 0.9992
 rs3212090 (XRCC3.S3) A G 15/44/32 2/16/11 0.4066 0.3448 0.68 0.33 1.38 0.2959 0.6733
 rs12432907 (XRCC3.S4) A G 18/47/26 7/11/11 0.4560 0.4310 0.82 0.42 1.62 0.5821 0.9502
 rs861539 (XRCC3.S5) T C 1/8/82 0/8/21 0.0550 0.1379 3.88 1.25 12.07 0.0116c 0.0632
 rs861544 (XRCC3.S6) T C 10/59/22 3/18/8 0.4341 0.4138 0.94 0.43 2.05 0.8795 0.9999
aTag SNPs were listed down the column according to their position on the target gene from the 5' to 3' end of the sense strand. bOR was 
calculated using A2 as a reference. SNP, single nucleotide polymorphism; A1, minor allele; A2, major allele; MAF, minor allele frequency; 
OR, odds ratio; L95, lower boundary of the 95% confidence interval; U95, upper boundary of the 95% confidence interval; Pasym, asymptotic 
P‑value; Pemp, empirical P‑value. XRCC1, X‑ray repair cross‑complementing protein‑1; XRCC3, X‑ray repair cross‑complementing protein‑3.
Table III. Summary of sliding window haplotype analysis of all the possible sizes based on omnibus test of the XRCC1 and 
XRCC3 genes.
    Most significant omnibus test
    -----------------------------------------------------------------------------------------
Gene NSNP First SW Last SW SW  Pasym Pemp
XRCC1 2 XRCC1.S1..XRCC1.S2 XRCC1.S5..XRCC1.S6 XRCC1.S4..XRCC1.S5 0.4500 0.9159
 3 XRCC1.S1..XRCC1.S3 XRCC1.S4..XRCC1.S6 XRCC1.S2..XRCC1.S4 0.2924 0.8450
 4 XRCC1.S1..XRCC1.S4 XRCC1.S3..XRCC1.S6 XRCC1.S2..XRCC1.S5 0.2925 0.8450
 5 XRCC1.S1..XRCC1.S5 XRCC1.S2..XRCC1.S6 XRCC1.S2..XRCC1.S6 0.0877 0.5960
 6 XRCC1.S1..XRCC1.S6 XRCC1.S1..XRCC1.S6 XRCC1.S1..XRCC1.S6 0.2633 0.8891
XRCC3 2 XRCC3.S1..XRCC3.S2 XRCC3.S5..XRCC3.S6 XRCC3.S5..XRCC3.S6 0.0147 0.1944
 3 XRCC3.S1..XRCC3.S3 XRCC3.S4..XRCC3.S6 XRCC3.S1..XRCC3.S3 0.0561 0.3531
 4 XRCC3.S1..XRCC3.S4 XRCC3.S3..XRCC3.S6 XRCC3.S1..XRCC3.S4 0.0301 0.3231
 5 XRCC3.S1..XRCC3.S5 XRCC3.S2..XRCC3.S6 XRCC3.S2..XRCC3.S6 0.1132 0.6833
 6 XRCC3.S1..XRCC3.S6 XRCC3.S1..XRCC3.S6 XRCC3.S1..XRCC3.S6 0.0339 0.4571
NSNP, number of single-nucleotide polymorphisms in this haplotype; SW, sliding window; Pasym, asymptotic P‑value; Pemp, empirical P‑value. 
XRCC1, X‑ray repair cross‑complementing protein‑1; XRCC3, X‑ray repair cross‑complementing protein‑3.
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information on common genetic variants of the XRCC1 and 
XRCC3 genes and their association with radiation‑induced 
fibrosis. Additional haplotype analysis was performed in 
order to investigate the effects of all the possible haplotypes 
on radiation‑induced fibrosis. No significant association 
was found in the SNPs in either single‑marker or haplotype 
analysis following multiple comparisons.
Radiation‑induced fibrosis, unlike normal wound healing, 
is a complex process that its endpoint is the result of accumu-
lated chronic inflammatory reactions (24). Since DNA is the 
critical target of ionizing radiation damage, it is hypothesized 
that functional variants in DNA repair genes may affect 
the DNA repair capacity and lead to variations in radiation 
sensitivity. XRCC1 and XRCC3 are two of the genes that are 
involved in DNA repair. The association of functional vari-
ants of these genes with radiation‑induced late complications 
was previously investigated with inconsistent results (25). The 
majority of the published studies included breast and prostate 
cancer patients in Caucasian populations. No association with 
rs25487 of XRCC1 and rs861539 of XRCC3 was identified. 
Our results were in line with findings reported by other studies 
with relatively large sample sizes (16,17). However, our results 
were in contrast to those reported by 3 studies performed in 
Saudi Arabian NPC patients by Alsbeih et al (4,5,18). Our 
results indicated a trend of possible association between 
rs861539 of XRCC3 and radiation‑induced fibrosis in Chinese 
NPC patients, but not rs25487 of XRCC1. In order to investi-
gate the heterogeneity between studies with a similar study 
design, forest plots of rs25487 and rs861539 were constructed 
based on genotyped data from our study and the most recent 
study by Alsbeih et al (18).
Moderate to significant heterogeneity was observed for 
rs25487 and rs861539. The discrepancies between studies may 
be due to variations in the study design, length of follow‑up 
period and allele frequencies in different ethnic groups. The 
MAFs of rs25487 obtained by Alsbeih et al (18) and the 
present study were 0.232 and 0.258, respectively. The MAFs of 
rs861539 obtained by Alsbeih et al (18) and the present study 
were 0.394 and 0.075, respectively. While the deviation of allele 
frequencies between the two studies was small for rs25487, an 
increased risk of developing fibrosis was not identified by the 
present study. The median follow‑up time was 8 years in the 
present study and 40 months in the study by Alsbeih et al (18). 
Since late toxicities may progress over time several years after 
post‑RT, the length of the follow‑up is significantly associated 
with the development of fibrosis.
Normal tissue radiosensitivity is a complex phenomenon. 
Unlike truncated proteins, such as ataxia telangiectasia 
mutated, particular functional variants in selected genes may 
not be sufficient to cause severe radiosensitivity. Apart from 
specific functional variants, the role of other common vari-
ants of candidate genes and their effect have not been clearly 
determined. This study aimed to investigate the association 
of common and functional variants of DNA repair genes with 
fibrosis in NPC patients. We captured certain common vari-
ants and constructed haplotype structures of all possible sizes 
using tag SNPs, in order to obtain more information on the 
effects of DNA repair genes. One of the major limitations of 
our study was the relatively small sample size. A small sample 
size may not have enough power to detect SNPs with small and 
modest effects. Genotyped SNPs with small and modest effects 
were possibly not the causal SNPs of this phenomenon, but 
served as surrogates of other SNPs in high linkage disequilib-
rium located in distant regions. In addition, the effect sizes of 
common variants are likely to be small, in contrast to the large 
effect caused by rare variants (26,27). Therefore, individual 
Figure 2. Forest plot of rs861539 (C vs. T) from the XRCC3 gene. Odd ratios (ORs) of the major allele (C) were obtained. The allele is protective when OR<1. 
CI, confidence interval; XRCC3, X‑ray repair cross‑complementing protein‑3.
Figure 1. Forest plot of rs25487 (G vs. A) from the XRCC1 gene. Odd ratios (ORs) of the major allele (G) were obtained. The allele is protective when OR<1. 
CI, confidence interval; XRCC1, X‑ray repair cross‑complementing protein‑1.
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common variants may not be ideal universal biomarkers for 
identification of radiosensitivity.
Two large cohort studies focusing on radiation‑induced 
toxicities developed in breast and prostate cancers were 
recently published (26,28). One study by Barnett et al (26), 
involving 1,613 breast and prostate cancer patients, captured 
common variants using tag SNPs with MAF<0.05 and func-
tional SNPs in 92 genes and found no association in any of the 
SNPs. Furthermore, a replication study by Talbot et al (28), 
involving 2,036 patients from three cohorts, captured 
43 candidate SNPs in 35 genes and found that TNF‑α may be 
associated with increased risk of radiation toxicities in breast 
cancer patients. No previously reported associations were 
found to be significant in those studies. The negative findings 
of the studies indicated that previously published SNPs may 
not exert clinical effects individually and significant SNPs 
may have small effect sizes.
The first genome‑wide association analysis focused 
on the association of African‑American prostate cancer 
patients with the risk of radiation‑induced erectile dysfunc-
tion suggested that cancer type and ethnicity may be genetic 
predictors (29). Based on our findings, the low‑frequency 
variant rs861539 may be an ethnic group‑specific marker 
in predicting radiation‑induced toxicities in Chinese 
NPC patients. The amount of radiation dose received by 
NPC patients is generally different from that received by 
breast and prostate cancers patients, regardless of the different 
RT methods. Non‑irradiated cells were shown to exhibit 
similar inflammatory responses as irradiated cells (30). In 
addition to genetic factors, epigenetic factors may also affect 
individual radiosensitivity. Large‑scale studies should also 
be conducted in combined ethnic groups with all the types 
of cancer that require RT as standard treatment, in order to 
investigate the effects of common and functional variants. 
With the advancements in technology, the genetic profiles of 
individual patients may be obtained to assess the risk effect or 
perform a combined analysis. In addition, meta‑analyses may 
be performed to assess the risk of radiation‑induced toxici-
ties in NPC patients and obtain more cancer type‑specific 
information. The Standardized Total Average Toxicity score 
can be used in future studies to enhance data pooling (31). 
Since normal tissue radiosensitivity may be the result of 
the combined effects of genes involved in different cellular 
pathways, functional study focus on the performance of 
DNA repair proteins following irradiation with respect to 
genotypes and epigenetic changes may be conducted. Casual 
common or functional variants may be used as pre‑treatment 
biomarkers for identifying highly radiosensitive cancer 
patients, leading to the customization of treatment protocols 
and improved treatment outcomes in the future.
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